Article

Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma

Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.

vemurafenib (Brand name:

Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.

Related Videos
Dr Chun Chao
Screenshot of an interview with Shaun McKenzie, MD
Brianna Rhue, OD, FAAO
Julie Rodman, OD, MS, FAAO
Nate Lighthizer, OD, FAAO
Lidia Schapira, MD, FASCO, professor of medicine at Stanford Medicine, medical oncologist, and director for the Stanford Cancer Institute and the Stanford Comprehensive Cancer Center
Mile Brujic, OD, FAAO
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo